Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Clinic Consultation charges
A small phase II trial reported limited efficacy of T-DM1 monotherapy in 15 relapsed HER2 -altered NSCLC patients with an objective response rate (ORR) of 6.7% and median progression-free survival (PFS) and overall survival (OS) of 2 (95% confidence interval [CI], 1.4 to 4) and 10.9 months (95% CI, 4.4 to 12), respectively
Trimmed reads were aligned by STAR 2.7.8.a with mouse reference index mm39
Our Peptide Program Starting at $125 Monthly In-person consultation with a board certified internal medicine physician Monthly check ins with a nurse Evaluation of treatment response each cycle by physician with apprpriate dose changes Initial and follow-up InBody assessments to track body composition changes
US$ 21.16
US$ 24.64
US$ 22.63
US$ 28.05
